Celgene Targets Cancer Stem Cells with US$3.3 B OncoMed Collaboration
By Heather Cartwright
Pharma Deals Review: Vol 2013 Issue 12 (Table of Contents)
Published: 19 Dec-2013
DOI: 10.3833/pdr.v2013.i12.1996 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Continuing its strategy of investing in novel therapeutic approaches in oncology via option-based deals, Celgene has formed a broad collaboration with OncoMed Pharmaceuticals that is potentially worth more than US$3...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS